One of the hardest parts of translational medicine is melding the two objectives of the academic institution versus the Pharmaceutical company. In a recap of a session from BIO-Europe®, Insight looks at some of the differences between the two entities. Academic institutions looks at the scientific vision and background. Pharma look at the patient needs and the therapeutic implications. Therefore, striking a balance between the scientific aspect and a version of a therapeutic that is usable for a patient is a hard bridge to cross. A number a of academic institutions participated in the discussion, each having different ways of working to get their science to a usable point into the hands of the Pharmaceutical companies. In the United States, there has been an effort to involve commercial aspects of development from the beginning in academic research – the same process is slowly spreading to European academic institutions. Other hurdles of developing the partnership is the time it takes to reach an agreement between the two companies.
When looking to invest in translational medicine, what is one key component you look for in the science you’re investing in?